Skip to main content
Industry News
HHS contracts with Emergent for COVID-19 vaccine production

Emergent BioSolutions was awarded a $628 million contract with the US government through the Biomedical Advanced Research and Development Authority to build COVID-19 vaccine manufacturing capacity. The task order requires Emergent to use its Baltimore Bayview facility, designed for rapid production of large quantities of treatments and vaccines during emergencies, for the production of COVID-19 vaccine candidates through 2021.

Full Story: